These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18507698)

  • 1. Loss of non-steroidal anti-inflammatory drug hypersensitivity after Helicobacter pylori eradication.
    Neynaber S; Berking C; Przybilla B
    J Eur Acad Dermatol Venereol; 2009 Feb; 23(2):196-7. PubMed ID: 18507698
    [No Abstract]   [Full Text] [Related]  

  • 2. Helicobacter pylori: a historical perspective 1983-2003.
    Fraser A
    N Z Med J; 2004 May; 117(1194):U896. PubMed ID: 15156214
    [No Abstract]   [Full Text] [Related]  

  • 3. Helicobacter pylori and non-malignant diseases.
    Furuta T; Delchier JC
    Helicobacter; 2009 Sep; 14 Suppl 1():29-35. PubMed ID: 19712165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial.
    De Leest HT; Steen KS; Bloemena E; Lems WF; Kuipers EJ; Van de Laar MA; Bijlsma JW; Janssen M; Houben HH; Kostense PJ; Boers M; Dijkmans BA
    J Clin Gastroenterol; 2009 Feb; 43(2):140-6. PubMed ID: 18797408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Maintenance treatment after success of H. pylori eradication].
    Aoyama N; Shirasaka D; Miki I
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():523-30. PubMed ID: 11979840
    [No Abstract]   [Full Text] [Related]  

  • 6. [Helicobacter pylori diagnostics--how, when and by whom?].
    Bytzer P
    Ugeskr Laeger; 2000 Sep; 162(38):5101-2. PubMed ID: 11014147
    [No Abstract]   [Full Text] [Related]  

  • 7. [The role of Helicobacter pylori and NSAIDS in upper gastrointestinal disease].
    Hu FL
    Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):722-3. PubMed ID: 12914005
    [No Abstract]   [Full Text] [Related]  

  • 8. Non-steroidal anti-inflammatory drugs request parity with Helicobacter pylori.
    Ladwa M; Takeuchi K; Bjarnason I
    Scand J Gastroenterol; 2006 Apr; 41(4):373-5. PubMed ID: 16635902
    [No Abstract]   [Full Text] [Related]  

  • 9. Helicobacter pylori and non-malignant diseases.
    Shirin H; Leja M; Niv Y
    Helicobacter; 2008 Oct; 13 Suppl 1():23-7. PubMed ID: 18783518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the treatment of patients with Helicobacter pylori.
    Zullo A; Vaira D
    Am Fam Physician; 2007 Sep; 76(5):633. PubMed ID: 17894129
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment and prophylaxis of alimentary tract lesions caused by non-steroid anti-inflammatory drugs].
    Gil J; Wojtuń S
    Pol Merkur Lekarski; 2009 May; 26(155):353-7. PubMed ID: 19606672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-steroid gastropathy combined with Helicobacter pylori: current problems].
    Akhmedov VA; Vinzhegina VA; Sudakova AN; Rozenblit EI
    Eksp Klin Gastroenterol; 2007; (1):64-6. PubMed ID: 17547117
    [No Abstract]   [Full Text] [Related]  

  • 13. Short-term/low-dose aspirin-induced duodenal erosions are not dependent on Helicobacter pylori infection, cyclooxygenase expression and prostaglandin E2 levels.
    Venerito M; Treiber G; Wex T; Kuester D; Roessner A; Mönkemüller K; Malfertheiner P
    Scand J Gastroenterol; 2008; 43(7):801-9. PubMed ID: 18584518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of nonsteroidal, anti-inflammatory, drug-associated dyspepsia.
    Gupta S; McQuaid K
    Gastroenterology; 2005 Nov; 129(5):1711-9. PubMed ID: 16285968
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bleeding peptic ulcer. Prevalence of Helicobacter pylori and use of nonsteroidal anti-inflammatory drugs/acetylsalicylic acid].
    Vestergård A; Bredahl K; de Muckadell OB; Pedersen OB; Hansen JM
    Ugeskr Laeger; 2009 Jan; 171(4):235-9. PubMed ID: 19174039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
    Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
    Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-steroid gastropathy: particular features of treatment].
    Vasil'ev IuV
    Eksp Klin Gastroenterol; 2007; (1):56-9. PubMed ID: 17547115
    [No Abstract]   [Full Text] [Related]  

  • 18. Definitions and classification of dyspepsia: pH, Helicobacter pylori, non-steroidal anti-inflammatory drugs--should we include gastro-oesophageal reflux disease?
    Bazzoli F
    Aliment Pharmacol Ther; 2005 Mar; 21 Suppl 1():15-6, 21-4. PubMed ID: 15755270
    [No Abstract]   [Full Text] [Related]  

  • 19. Helicobacter heilmannii reinfection in a Helicobacter pylori negative adolescent: a 4-year follow-up.
    Siala K; Sýkora J; Hes O; Varvarovská J; Pazdiora P
    J Clin Gastroenterol; 2007 Feb; 41(2):221-2. PubMed ID: 17245224
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship between Helicobacter pylori and chronic urticaria.
    Sadighha A; Shirali R; Zahed GM
    J Eur Acad Dermatol Venereol; 2009 Feb; 23(2):198-9. PubMed ID: 18435737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.